Credit Suisse Group started coverage on shares of Envision Healthcare (NYSE:EVHC) in a report published on Monday morning. The firm issued an outperform rating and a $36.00 target price on the stock.
A number of other equities analysts have also weighed in on the stock. Canaccord Genuity reaffirmed a buy rating and issued a $32.00 target price (down from $68.00) on shares of Envision Healthcare in a research note on Thursday, November 2nd. Robert W. Baird restated a buy rating and set a $70.00 target price on shares of Envision Healthcare in a research report on Tuesday, October 17th. SunTrust Banks set a $55.00 price target on shares of Envision Healthcare and gave the stock a buy rating in a research report on Sunday, October 15th. Bank of America dropped their price objective on shares of Envision Healthcare from $72.00 to $60.00 and set a buy rating for the company in a research note on Monday, October 9th. Finally, Jefferies Group set a $71.00 price objective on shares of Envision Healthcare and gave the company a buy rating in a research note on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Envision Healthcare currently has an average rating of Buy and a consensus price target of $46.80.
Envision Healthcare (NYSE:EVHC) traded up $0.83 during trading hours on Monday, hitting $32.90. 4,069,400 shares of the stock were exchanged, compared to its average volume of 2,251,147. Envision Healthcare has a 52 week low of $23.77 and a 52 week high of $73.00. The company has a quick ratio of 3.00, a current ratio of 3.01 and a debt-to-equity ratio of 0.89. The company has a market capitalization of $3,876.92, a PE ratio of 9.90, a P/E/G ratio of 0.83 and a beta of 0.57.
Envision Healthcare (NYSE:EVHC) last posted its quarterly earnings data on Tuesday, October 31st. The company reported $0.73 earnings per share for the quarter, missing the consensus estimate of $0.81 by ($0.08). Envision Healthcare had a positive return on equity of 4.88% and a negative net margin of 6.39%. The company had revenue of $1.99 billion during the quarter, compared to the consensus estimate of $2.03 billion. During the same quarter last year, the firm earned $1.13 EPS. The business’s revenue for the quarter was up 142.0% on a year-over-year basis. analysts anticipate that Envision Healthcare will post 2.57 earnings per share for the current fiscal year.
Envision Healthcare announced that its board has approved a share repurchase program on Monday, September 18th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the company to purchase up to 4.5% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its stock is undervalued.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Commonwealth Bank of Australia lifted its position in shares of Envision Healthcare by 24.3% during the second quarter. Commonwealth Bank of Australia now owns 2,096 shares of the company’s stock valued at $130,000 after purchasing an additional 410 shares in the last quarter. LMR Partners LLP purchased a new position in Envision Healthcare in the 2nd quarter worth approximately $205,000. Cutter & CO Brokerage Inc. grew its stake in Envision Healthcare by 11.1% in the 2nd quarter. Cutter & CO Brokerage Inc. now owns 3,668 shares of the company’s stock worth $230,000 after buying an additional 367 shares in the last quarter. Flinton Capital Management LLC grew its stake in Envision Healthcare by 18.7% in the 2nd quarter. Flinton Capital Management LLC now owns 4,464 shares of the company’s stock worth $280,000 after buying an additional 704 shares in the last quarter. Finally, D.A. Davidson & CO. grew its stake in Envision Healthcare by 30.0% in the 2nd quarter. D.A. Davidson & CO. now owns 4,589 shares of the company’s stock worth $287,000 after buying an additional 1,059 shares in the last quarter.
TRADEMARK VIOLATION WARNING: “Envision Healthcare (EVHC) Now Covered by Analysts at Credit Suisse Group” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/12/envision-healthcare-evhc-now-covered-by-analysts-at-credit-suisse-group.html.
About Envision Healthcare
Envision Healthcare Holdings, Inc, formerly CDRT Holding Corporation, is a holding company. The Company, through its subsidiary, provides physician-led medical services in the United States. It operates in two segments: EmCare Holdings, Inc (EmCare) and American Medical Response, Inc (AMR). Its EmCare segment is a provider of integrated facility-based and post-acute care physician services to healthcare facilities in the United States.
Receive News & Ratings for Envision Healthcare Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envision Healthcare Co. and related companies with MarketBeat.com's FREE daily email newsletter.